Gene expression of human angiosarcoma
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA939728 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Gene expression profiling of human angiosarcoma
| PRJNA685808 | ENA
Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel
2023-05-03 | GSE226338 | GEO
Project description:A comparison of gene expression in OCT frozen human angiosarcoma compared with OCT frozen normal mesenchymal tissues
2013-10-21 | GSE44115 | GEO
Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel
2020-12-01 | GSE162370 | GEO
Project description:Gene expression of human angiosarcoma and correlation with treatment outcomes
| PRJNA681613 | ENA
Project description:We generated RNA-Seq data from human angiosarcoma tissues (N=13) and non-malignant tissue samples (N=6). The goal of this study was to determine differentially expressed genes in the tumors compared to controls. We sequenced about 80 – 100 million sequence reads per sample and mapped to the human reference genome (GRCh38). We identified 1,237 differentially expressed genes between the tumors and non-malignant controls (FDR P-value < 0.05): 490 genes were upregulated and 747 genes were downregulated in angiosarcomas. Our results show a comprehensive data of fusion genes and gene expression profile in human angiosarcomas using RNA-seq technology.
2020-12-17 | GSE163359 | GEO
Project description:We first use microRNA expression profiles to find miRNA expression signatures in 3 cases of human angiosarcoma and capillary hemangiomauman, then RT-PCR for large sample verification. Through the bioinformatics prediction of its target genes, we study its function and aim to find the new molecular markers and therapeutic targets.
2015-02-06 | GSE65657 | GEO
Project description:A comparison of gene expression in OCT frozen human angiosarcoma compared with OCT frozen normal mesenchymal tissues RNA was isolated from 18 AS and normal human. RNA was isolated from 3 kidney and 2 skeletal muscle OCT frozen sections and 3 samples of frozen whole blood. Twenty-five nanograms of total RNA from each sample was used for amplification, and then was fluorescently labeled using Cy3 and hybridized onto Agilent whole human genome 8x60k gene expression microarrays (Agilent Technologies, Santa Clara, CA) according to Agilent standard procedures. After hybridization for 17 h at 65 oC and 10 rpm, the arrays were washed and scanned with the Agilent G3 high-resolution scanner. Probe features were extracted from the microarray scan data using Feature Extraction software v.10.7.3.1 (Agilent Technologies). Microarray data was read and processed with R/Bioconductor (version 2.15.1/2.16) statistical software environment using the limma package (version 3.12.1). The raw data was within array quantile normalized and probes that mapped to the same gene were combined by averaging.
2013-10-21 | E-GEOD-44115 | biostudies-arrayexpress
Project description:We first use microRNA expression profiles to find miRNA expression signatures in 3 cases of human angiosarcoma and capillary hemangiomauman, then RT-PCR for large sample verification. Through the bioinformatics prediction of its target genes, we study its function and aim to find the new molecular markers and therapeutic targets. We identified the miRNA expression signatures in human angiosarcomas and capillary hemangiomas by using microRNA expression profiles
2015-02-06 | E-GEOD-65657 | biostudies-arrayexpress
Project description:Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, one of the taxanes (genotoxic drugs), although it has a limited effect due to chemoresistance for prolonged treatment. Here we examine a new angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We first find that the chemotherapeutic drugs, cisplatin and paclitaxel, efficiently induce cellular senescence of angiosarcoma cells. Subsequent treatment with a senolytic agent, ABT-263, eliminates senescent cells through the activation of the apoptotic pathway. In addition, expression analysis indicates that senescence-associated secretory phenotype (SASP) genes are activated in senescent angiosarcoma cells and that ABT-263 treatment eliminates senescent cells expressing genes in the type-I interferon (IFN-I) pathway. Moreover, we show that cisplatin treatment alone requires a high dose to remove angiosarcoma cells, whereas a lower dose of cisplatin is sufficient to induce senescence, followed by the elimination of senescent cells by senolytic treatment. This study sheds light on a potential therapeutic strategy against angiosarcoma by combining a relatively low dose of cisplatin with the ABT-263 senolytic agent, which can help ease the deleterious side effects of chemotherapy.
2024-03-23 | GSE245935 | GEO